Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGAV | P06756 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.35 |
| ▸ | ITGAL | P20701 | 2/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736542 | 0.96 | NOS2 (0.37) | NOS2ITGB1ITGA4ITGB7TAS1R3 | |
| SCHEMBL22016798 | 0.94 | NPC1 (0.37) | NOS2ITGB1ITGA4TAS1R3TAS1R1 | |
| SCHEMBL24198686 | 0.91 | ITGB1 (0.42) | NOS2ITGB1ITGA4ITGB7TAS1R3 | |
| SCHEMBL29736530 | 0.91 | ITGB1 (0.42) | NOS2ITGB1ITGA4ITGB7TAS1R3 | |
| SCHEMBL29736602 | 0.90 | NPC1 (0.36) | NOS2ITGB1ITGA4TAS1R3TAS1R1 | |
| SCHEMBL21955007 | 0.90 | ITGB1 (0.46) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL21955008 | 0.90 | ITGB1 (0.46) | ITGB1ITGA4ITGB7ITGA5ITGB3 | |
| SCHEMBL24198691 | 0.89 | NLRP3 (0.37) | NOS2ITGB1ITGA4ITGB7ITGA5 | |
| SCHEMBL22017357 | 0.88 | CNR2 (0.36) | NOS2ITGB1ITGA4ITGB7TAS1R3 | |
| SCHEMBL24198689 | 0.87 | NOS2 (0.35) | NOS2ITGB1ITGA4ITGB7ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | NOS2 2639/4885ITGB1 4/4885ITGA4 3/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | NOS2 2639/4885ITGB1 4/4885ITGA4 3/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | NOS2 2639/4885ITGB1 4/4885ITGA4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.